VentriPoint Diagnostics Ltd V.VPT

The return flights from a trip to Europe

[jopatclo]

Hugh MacNaughtHugh MacNaught • Following • FollowingPresident and CEO at Ventripoint Diagnostics Ltd.President and CEO at Ventripoint Diagnostics Ltd.4m •    4 minutes ago

 

The return flights from a trip to Europe that that was highlighted by the AEPC congress in Porto, Portugal and meetings with clinicians in Italy provided an opportunity to reflect on what I was able to observe and experience over the past nine days.

I was very encouraged to see the way that the Ventripoint team (including our distribution partners AngioPro and Cardiologic) worked to create the display booth and marketing materials, collaborate with Dr. Kai Laser to plan and deliver the VMS+ workshops, and engage with numerous delegates during the congress. Nearly 10% of the attendees registered to participate in our workshops which indicates a growing awareness of the benefits that VMS+ offers. The team is now following up with attendees and will assist those who are motivated to adopt VMS+ into clinical practice.

While in Italy it was interesting to learn of the limitations to workflow inherent to cMRI, and that there is an interest in the ability of VMS+ to streamline workflow, shorten turnaround times and improve the adult patient experience. Our discussions were focused towards right side heart function, and the potential to use VMS+ to assess patients suspected of having diseased or damaged tricuspid valves.

Historically there has been somewhat of a tendency to overlook the functioning of the right side of the heart because of the difficulties in imaging it with modalities such as 2D echo. Right side functioning is now known to play a key role in determining clinical status and outcomes in patients with pulmonary hypertension, cardiomyopathies, and congenital heart disease.

We are clearly at a stage where our product is evolving from being used in clinical research applications to where it is a valued tool in routine practice and a growing number of clinicians are showing interest in adopting it. Given the progress shown in the UK and Europe I am now able to turn my attention to the US market and will be engaging more fully in the outreach to American clinicians and patient advocacy groups.

AI enhanced echo is an important tool in the management of cardiology patients, and VMS+ is uniquely positioned to provide clinicians with essential volumetric measurements, particularly for the right ventricle. Adoption of VMS+ into clinical practice enables routine monitoring of patients and timely insights into the effectiveness of treatment - rapidly, affordably and with cMRI levels of accuracy.